- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06459635
Estudio de predicción de la fase del dolor del ataque de migraña (PREDI-CRISIS)
Estudio de predicción de la fase de dolor de los ataques de migraña en pacientes con migraña episódica
The study of the ability to predict pain in a migraine attack, through premonitory symptoms and through an ambulatory monitoring device through real-time recording of hemodynamic variables, is one of the strategic lines of research of the unit. of Headaches at the Hospital de La Princesa since 2013 together with the Complutense and Polytechnic University of Madrid. Their results have been reflected in various publications (Pagán J, et al. Sensors 2015; Gago-Veiga AB, et al. J Pain Res 2018) and have promoted the creation of several invention patents.
Descripción general del estudio
Estado
Descripción detallada
Patients with episodic migraine will be recruited from the monographic headache clinics of the 7 centers participating in the study. These patients, for a maximum period of 2 months, must monitor their hemodynamic variables with a wearable device and record all the clinical characteristics of their migraine attacks. Subsequently, with these records, an individualized algorithm will be created for each patient that aims to predict the onset of the migraine attack.
Tipo de estudio
Inscripción (Actual)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Madrid
-
Madrid, Madrid, España, 28006
- Hospital Universitario de La Princesa
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Patients aged between 18 and 65 years with a diagnosis of episodic migraine who have between 4 and 14 days of headache per month. These patients will come from 7 Headache Units in Spain belonging to the following hospitals: • La Princesa University Hospital • Vall 'Hebron University Hospital • Marqués de Valdecilla University Hospital • Valladolid University Clinical Hospital • Donostia University Hospital • Lozano Blesa University Clinical Hospital • La Fe Polytechnic University Hospital
Descripción
Inclusion Criteria:
- Age between 15 years and 69 years.
- Diagnosed with migraine by a headache neurologist and according to the criteria proposed by ICHD-3.
- History of migraine of at least 1 year of evolution.
- Normal neurological examination.
- Have given your informed consent.
- Be able to describe your clinical situation and the characteristics of your headache.
- Have an average of 10 to 14 migraine days per month in the three months prior to inclusion (high-frequency episodic migraine).
- User-level management capacity of "smartphone" type electronic devices.
- Be able to complete two months of study follow-up.
Exclusion Criteria:
- Presence of another type of headache, with the exception of headache due to excessive use of analgesic medication.
- Cognitive deficiency or any other pathology that may prevent or make it difficult for the patient to perform the study correctly.
- Neurological focus in the examination.
- Pregnancy or breastfeeding period.
- Patients with known heart disease or bronchopathy, Sjögren's syndrome, diabetes mellitus, or hypo/hyperthyroidism.
- Carriers of pacemakers, neurostimulators or any other electronic device that is considered to make the interpretation of biometric records difficult.
- Anatomical problem that makes the use of the device impossible.
- Patients in whom it is expected that a change in migraine preventive treatment or other usual treatment will be possible during the study period.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: CASE_CONTROL
- Perspectivas temporales: PROSPECTIVE
Cohortes e Intervenciones
Grupo / Cohorte |
|---|
|
Patients with episodic migraine
Patients with episodic migraine who present between 4 and 10 migraine attacks per month. These patients must have a diagnosis of migraine by a headache neurologist and according to the criteria proposed by ICHD-3. In addition, they must present at least 1 year of evolution of the migraine, as well as a normal neurological examination and have given their informed consent. |
|
Control patients
People who have never had a headache episode with migraine characteristics. These may present, at most, one episode per month of headache with non-migraine characteristics in the last 3 months. In turn, they should not have a family history of migraine (1st and 2nd degree). |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Development of a prediction strategy for the onset of migraine
Periodo de tiempo: From the beginning of treatment, which is the initial visit, to 2 months of follow-up
|
Develop a prediction strategy for the onset of migraine attacks in patients with episodic migraine, based on hemodynamic and clinical variables of migraine attacks. |
From the beginning of treatment, which is the initial visit, to 2 months of follow-up
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Posibility of predict the onset of pain in a migraine attack
Periodo de tiempo: From the beginning of treatment, which is the initial visit, to 2 months of follow-up
|
To analyze whether it is possible to predict the onset of pain in a migraine attack, through ambulatory and non-invasive monitoring of physiological variables. |
From the beginning of treatment, which is the initial visit, to 2 months of follow-up
|
|
Individualized prediction algorithm
Periodo de tiempo: From the beginning of treatment, which is the initial visit, to 2 months of follow-up
|
Implement an individualized prediction algorithm that allows real-time prediction of the symptomatic phase of the migraine attack. |
From the beginning of treatment, which is the initial visit, to 2 months of follow-up
|
|
Effectiveness of the prediction model
Periodo de tiempo: From the beginning of treatment, which is the initial visit, to 2 months of follow-up
|
Measure the effectiveness of the prediction model both at the individual level and in a large group of patients. |
From the beginning of treatment, which is the initial visit, to 2 months of follow-up
|
Colaboradores e Investigadores
Colaboradores
Investigadores
- Investigador principal: Ana Beatriz Gago Veiga, Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Publicaciones y enlaces útiles
Publicaciones Generales
- Gago-Veiga AB, Pagan J, Henares K, Heredia P, Gonzalez-Garcia N, De Orbe MI, Ayala JL, Sobrado M, Vivancos J. To what extent are patients with migraine able to predict attacks? J Pain Res. 2018 Sep 27;11:2083-2094. doi: 10.2147/JPR.S175602. eCollection 2018.
- Pagan J, De Orbe MI, Gago A, Sobrado M, Risco-Martin JL, Mora JV, Moya JM, Ayala JL. Robust and Accurate Modeling Approaches for Migraine Per-Patient Prediction from Ambulatory Data. Sensors (Basel). 2015 Jun 30;15(7):15419-42. doi: 10.3390/s150715419.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
- Migraña
- Dolor de cabeza
- algoritmo
- Predicción
- Predecir
- algoritmo de predicción
- predicción del dolor de cabeza
- predecir dolor de cabeza
- predicción de migraña
- predecir la migraña
- ataques de migraña
- ataque de migraña
- ataque de dolor de cabeza
- predicción de ataque de migraña
- predecir el ataque de migraña
Términos MeSH relevantes adicionales
- Dolor
- Manifestaciones neurológicas
- Enfermedades Cerebrales
- Enfermedades del Sistema Nervioso Central
- Enfermedades del Sistema Nervioso
- Trastornos de cefalea primaria
- Trastornos de dolor de cabeza
- Condiciones Patológicas, Signos y Síntomas
- Signos y síntomas
- Trastornos de migraña
- Dolor de cabeza
- Migraña con Aura
- Migraña sin aura
Otros números de identificación del estudio
- 3513
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Individual participant data (IPD) will not be shared with other researchers. This decision is based on data protection and confidentiality requirements in accordance with applicable European and national regulations (including GDPR). Given that this is a multicentre observational study conducted in routine clinical practice, access to IPD is restricted to the study investigators for the purposes of the predefined analyses.
Any potential secondary use of the dataset would only be considered in fully anonymized form and subject to prior ethical approval and compliance with applicable data protection legislation.
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .